Skip to main content
NCBI home page
Transactions of the American Clinical and Climatological Association logoLink to Transactions of the American Clinical and Climatological Association
. 2000;111:201–241.

The Gordon Wilson Lecture. Natural history and treatment of early stage prostate cancer.

P T Scardino 1
PMCID: PMC2194384  PMID: 10881343

Abstract

Prostate cancer poses a challenge to society and to physicians. It is a remarkably prevalent tumor, perhaps the most common cancer in the world in its histologic manifestation. In its clinically apparent form, it is notably heterogeneous. Some patients live out their lives with a prostate cancer that remains stable for decades without treatment. In other cases, the cancer grows aggressively, responds poorly to therapy, and causes death within a few years. The median loss-of-life expectancy for men diagnosed with prostate cancer has been estimated at 9 years. Important advances have been made in the past two decades in the treatment of prostate cancer. Further progress will require more accurate characterization of the primary tumor in each individual patient to tailor treatment--whether conservative or aggressive, surgery or radiation--more accurately to the nature of the individual cancer. Imaging studies in particular must be improved if we are to have better, noninvasive ways to identify the presence of a cancer and to define its volume, location, and extent. Substantial progress against this disease will require major breakthroughs in our understanding of the etiology of prostate cancer, the development of effective chemopreventive agents, more accurate ways to assess the biological potential of the tumor, and more effective systemic agents to treat metastatic cancer.

Full text

PDF
201

Images in this article

208Fig. 1
on p.208

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbas F., Scardino P. T. Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary. Urol Clin North Am. 1996 Nov;23(4):587–604. doi: 10.1016/s0094-0143(05)70338-4. [DOI] [PubMed] [Google Scholar]
  2. Adolfsson J., Rönström L., Löwhagen T., Carstensen J., Hedlund P. O. Deferred treatment of clinically localized low grade prostate cancer: the experience from a prospective series at the Karolinska Hospital. J Urol. 1994 Nov;152(5 Pt 2):1757–1760. doi: 10.1016/s0022-5347(17)32379-0. [DOI] [PubMed] [Google Scholar]
  3. Albertsen P. C., Fryback D. G., Storer B. E., Kolon T. F., Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA. 1995 Aug 23;274(8):626–631. [PubMed] [Google Scholar]
  4. Albertsen P. C., Hanley J. A., Gleason D. F., Barry M. J. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998 Sep 16;280(11):975–980. doi: 10.1001/jama.280.11.975. [DOI] [PubMed] [Google Scholar]
  5. Asbell S. O., Krall J. M., Pilepich M. V., Baerwald H., Sause W. T., Hanks G. E., Perez C. A. Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys. 1988 Dec;15(6):1307–1316. doi: 10.1016/0360-3016(88)90225-8. [DOI] [PubMed] [Google Scholar]
  6. Babaian R. J., Sayer J., Podoloff D. A., Steelhammer L. C., Bhadkamkar V. A., Gulfo J. V. Radioimmunoscintigraphy of pelvic lymph nodes with 111indium-labeled monoclonal antibody CYT-356. J Urol. 1994 Dec;152(6 Pt 1):1952–1955. doi: 10.1016/s0022-5347(17)32277-2. [DOI] [PubMed] [Google Scholar]
  7. Bagshaw M. A., Cox R. S., Ray G. R. Status of radiation treatment of prostate cancer at Stanford University. NCI Monogr. 1988;(7):47–60. [PubMed] [Google Scholar]
  8. Bastacky S. I., Wojno K. J., Walsh P. C., Carmichael M. J., Epstein J. I. Pathological features of hereditary prostate cancer. J Urol. 1995 Mar;153(3 Pt 2):987–992. [PubMed] [Google Scholar]
  9. Berges R. R., Vukanovic J., Epstein J. I., CarMichel M., Cisek L., Johnson D. E., Veltri R. W., Walsh P. C., Isaacs J. T. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res. 1995 May;1(5):473–480. [PMC free article] [PubMed] [Google Scholar]
  10. Bolla M., Gonzalez D., Warde P., Dubois J. B., Mirimanoff R. O., Storme G., Bernier J., Kuten A., Sternberg C., Gil T. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997 Jul 31;337(5):295–300. doi: 10.1056/NEJM199707313370502. [DOI] [PubMed] [Google Scholar]
  11. Bostwick D. G. Practical clinical application of predictive factors in prostate cancer. A review with an emphasis on quantitative methods in tissue specimens. Anal Quant Cytol Histol. 1998 Oct;20(5):323–342. [PubMed] [Google Scholar]
  12. Bostwick D. G. Prostatic intraepithelial neoplasia (PIN). Urology. 1989 Dec;34(6 Suppl):16–22. [PubMed] [Google Scholar]
  13. Breslow N., Chan C. W., Dhom G., Drury R. A., Franks L. M., Gellei B., Lee Y. S., Lundberg S., Sparke B., Sternby N. H. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer. 1977 Nov 15;20(5):680–688. doi: 10.1002/ijc.2910200506. [DOI] [PubMed] [Google Scholar]
  14. Burnett A. L., Chan D. W., Brendler C. B., Walsh P. C. The value of serum enzymatic acid phosphatase in the staging of localized prostate cancer. J Urol. 1992 Dec;148(6):1832–1834. doi: 10.1016/s0022-5347(17)37042-8. [DOI] [PubMed] [Google Scholar]
  15. Byar D. P., Mostofi F. K. Carcinoma of the prostate: prognostic evaluation of certain pathologic features in 208 radical prostatectomies. Examined by the step-section technique. Cancer. 1972 Jul;30(1):5–13. doi: 10.1002/1097-0142(197207)30:1<5::aid-cncr2820300103>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  16. Carter B. S., Beaty T. H., Steinberg G. D., Childs B., Walsh P. C. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3367–3371. doi: 10.1073/pnas.89.8.3367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Carter B. S., Bova G. S., Beaty T. H., Steinberg G. D., Childs B., Isaacs W. B., Walsh P. C. Hereditary prostate cancer: epidemiologic and clinical features. J Urol. 1993 Sep;150(3):797–802. doi: 10.1016/s0022-5347(17)35617-3. [DOI] [PubMed] [Google Scholar]
  18. Carter H. B., Pearson J. D., Metter E. J., Brant L. J., Chan D. W., Andres R., Fozard J. L., Walsh P. C. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992 Apr 22;267(16):2215–2220. [PMC free article] [PubMed] [Google Scholar]
  19. Carter H. B., Piantadosi S., Isaacs J. T. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol. 1990 Apr;143(4):742–746. doi: 10.1016/s0022-5347(17)40078-4. [DOI] [PubMed] [Google Scholar]
  20. Catalona W. J., Partin A. W., Slawin K. M., Brawer M. K., Flanigan R. C., Patel A., Richie J. P., deKernion J. B., Walsh P. C., Scardino P. T. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998 May 20;279(19):1542–1547. doi: 10.1001/jama.279.19.1542. [DOI] [PubMed] [Google Scholar]
  21. Catalona W. J., Richie J. P., Ahmann F. R., Hudson M. A., Scardino P. T., Flanigan R. C., deKernion J. B., Ratliff T. L., Kavoussi L. R., Dalkin B. L. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994 May;151(5):1283–1290. doi: 10.1016/s0022-5347(17)35233-3. [DOI] [PubMed] [Google Scholar]
  22. Catalona W. J., Smith D. S. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol. 1994 Nov;152(5 Pt 2):1837–1842. doi: 10.1016/s0022-5347(17)32397-2. [DOI] [PubMed] [Google Scholar]
  23. Catalona W. J., Smith D. S., Ratliff T. L., Basler J. W. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993 Aug 25;270(8):948–954. [PubMed] [Google Scholar]
  24. Catalona W. J., Smith D. S., Ratliff T. L., Dodds K. M., Coplen D. E., Yuan J. J., Petros J. A., Andriole G. L. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991 Apr 25;324(17):1156–1161. doi: 10.1056/NEJM199104253241702. [DOI] [PubMed] [Google Scholar]
  25. Chan E. C., Sulmasy D. P. What should men know about prostate-specific antigen screening before giving informed consent? Am J Med. 1998 Oct;105(4):266–274. doi: 10.1016/s0002-9343(98)00257-5. [DOI] [PubMed] [Google Scholar]
  26. Chodak G. W., Thisted R. A., Gerber G. S., Johansson J. E., Adolfsson J., Jones G. W., Chisholm G. D., Moskovitz B., Livne P. M., Warner J. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994 Jan 27;330(4):242–248. doi: 10.1056/NEJM199401273300403. [DOI] [PubMed] [Google Scholar]
  27. Christensson A., Laurell C. B., Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem. 1990 Dec 27;194(3):755–763. doi: 10.1111/j.1432-1033.1990.tb19466.x. [DOI] [PubMed] [Google Scholar]
  28. Chybowski F. M., Keller J. J., Bergstralh E. J., Oesterling J. E. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol. 1991 Feb;145(2):313–318. doi: 10.1016/s0022-5347(17)38325-8. [DOI] [PubMed] [Google Scholar]
  29. Cooner W. H. Rectal examination and ultrasonography in the diagnosis of prostate cancer. Prostate Suppl. 1992;4:3–10. doi: 10.1002/pros.2990210503. [DOI] [PubMed] [Google Scholar]
  30. D'Amico A. V., Whittington R., Malkowicz S. B., Schultz D., Blank K., Broderick G. A., Tomaszewski J. E., Renshaw A. A., Kaplan I., Beard C. J. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998 Sep 16;280(11):969–974. doi: 10.1001/jama.280.11.969. [DOI] [PubMed] [Google Scholar]
  31. DeAntoni E. P., Crawford E. D., Oesterling J. E., Ross C. A., Berger E. R., McLeod D. G., Staggers F., Stone N. N. Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. Urology. 1996 Aug;48(2):234–239. doi: 10.1016/s0090-4295(96)00091-x. [DOI] [PubMed] [Google Scholar]
  32. Dillioglugil O., Leibman B. D., Kattan M. W., Seale-Hawkins C., Wheeler T. M., Scardino P. T. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology. 1997 Jul;50(1):93–99. doi: 10.1016/S0090-4295(97)00106-4. [DOI] [PubMed] [Google Scholar]
  33. Dillioglugil O., Leibman B. D., Leibman N. S., Kattan M. W., Rosas A. L., Scardino P. T. Risk factors for complications and morbidity after radical retropubic prostatectomy. J Urol. 1997 May;157(5):1760–1767. [PubMed] [Google Scholar]
  34. Eastham J. A., Kattan M. W., Rogers E., Goad J. R., Ohori M., Boone T. B., Scardino P. T. Risk factors for urinary incontinence after radical prostatectomy. J Urol. 1996 Nov;156(5):1707–1713. [PubMed] [Google Scholar]
  35. Elder J. S., Jewett H. J., Walsh P. C. Radical perineal prostatectomy for clinical stage B2 carcinoma of the prostate. J Urol. 1982 Apr;127(4):704–706. doi: 10.1016/s0022-5347(17)54005-7. [DOI] [PubMed] [Google Scholar]
  36. Epstein J. I., Carmichael M., Walsh P. C. Adenocarcinoma of the prostate invading the seminal vesicle: definition and relation of tumor volume, grade and margins of resection to prognosis. J Urol. 1993 May;149(5):1040–1045. doi: 10.1016/s0022-5347(17)36291-2. [DOI] [PubMed] [Google Scholar]
  37. Epstein J. I., Walsh P. C., Carmichael M., Brendler C. B. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994 Feb 2;271(5):368–374. [PubMed] [Google Scholar]
  38. Forman J. D., Kumar R., Haas G., Montie J., Porter A. T., Mesina C. F. Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: effects on the volume of normal tissue irradiation. Cancer Invest. 1995;13(1):8–15. doi: 10.3109/07357909509024889. [DOI] [PubMed] [Google Scholar]
  39. Fowler F. J., Jr, Barry M. J., Lu-Yao G., Roman A., Wasson J., Wennberg J. E. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993). Urology. 1993 Dec;42(6):622–629. doi: 10.1016/0090-4295(93)90524-e. [DOI] [PubMed] [Google Scholar]
  40. Fuks Z., Leibel S. A., Wallner K. E., Begg C. B., Fair W. R., Anderson L. L., Hilaris B. S., Whitmore W. F. The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys. 1991 Aug;21(3):537–547. doi: 10.1016/0360-3016(91)90668-t. [DOI] [PubMed] [Google Scholar]
  41. Geary E. S., Dendinger T. E., Freiha F. S., Stamey T. A. Incontinence and vesical neck strictures following radical retropubic prostatectomy. Urology. 1995 Jun;45(6):1000–1006. doi: 10.1016/s0090-4295(99)80121-6. [DOI] [PubMed] [Google Scholar]
  42. Geary E. S., Dendinger T. E., Freiha F. S., Stamey T. A. Nerve sparing radical prostatectomy: a different view. J Urol. 1995 Jul;154(1):145–149. [PubMed] [Google Scholar]
  43. Gerber G. S., Thisted R. A., Scardino P. T., Frohmuller H. G., Schroeder F. H., Paulson D. F., Middleton A. W., Jr, Rukstalis D. B., Smith J. A., Jr, Schellhammer P. F. Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA. 1996 Aug 28;276(8):615–619. [PubMed] [Google Scholar]
  44. Gibbons R. P., Correa R. J., Jr, Brannen G. E., Mason J. T. Total prostatectomy for localized prostatic cancer. J Urol. 1984 Jan;131(1):73–76. doi: 10.1016/s0022-5347(17)50210-4. [DOI] [PubMed] [Google Scholar]
  45. Gibbons R. P., Correa R. J., Jr, Brannen G. E., Weissman R. M. Total prostatectomy for clinically localized prostatic cancer: long-term results. J Urol. 1989 Mar;141(3):564–566. doi: 10.1016/s0022-5347(17)40895-0. [DOI] [PubMed] [Google Scholar]
  46. Gleason D. F. Classification of prostatic carcinomas. Cancer Chemother Rep. 1966 Mar;50(3):125–128. [PubMed] [Google Scholar]
  47. Gohagan J. K., Prorok P. C., Kramer B. S., Cornett J. E. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. J Urol. 1994 Nov;152(5 Pt 2):1905–1909. doi: 10.1016/s0022-5347(17)32412-6. [DOI] [PubMed] [Google Scholar]
  48. Goldenberg S. L., Klotz L. H., Srigley J., Jewett M. A., Mador D., Fradet Y., Barkin J., Chin J., Paquin J. M., Bullock M. J. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group. J Urol. 1996 Sep;156(3):873–877. [PubMed] [Google Scholar]
  49. Goldstein I., Feldman M. I., Deckers P. J., Babayan R. K., Krane R. J. Radiation-associated impotence. A clinical study of its mechanism. JAMA. 1984 Feb 17;251(7):903–910. doi: 10.1001/jama.251.7.903. [DOI] [PubMed] [Google Scholar]
  50. Gomella L. G., Raj G. V., Moreno J. G. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer. J Urol. 1997 Aug;158(2):326–337. [PubMed] [Google Scholar]
  51. Goto Y., Ohori M., Arakawa A., Kattan M. W., Wheeler T. M., Scardino P. T. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol. 1996 Sep;156(3):1059–1063. [PubMed] [Google Scholar]
  52. Hanks G. E. External-beam radiation therapy for clinically localized prostate cancer: patterns of care studies in the United States. NCI Monogr. 1988;(7):75–84. [PubMed] [Google Scholar]
  53. Hanks G. E., Martz K. L., Diamond J. J. The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys. 1988 Dec;15(6):1299–1305. doi: 10.1016/0360-3016(88)90224-6. [DOI] [PubMed] [Google Scholar]
  54. Haseman M. K., Reed N. L., Rosenthal S. A. Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen. Positron emission tomography and biopsy correlation. Clin Nucl Med. 1996 Sep;21(9):704–713. doi: 10.1097/00003072-199609000-00007. [DOI] [PubMed] [Google Scholar]
  55. Hodge K. K., McNeal J. E., Terris M. K., Stamey T. A. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol. 1989 Jul;142(1):71–75. doi: 10.1016/s0022-5347(17)38664-0. [DOI] [PubMed] [Google Scholar]
  56. Hollander J. B., Stiff C. A. Complete penile corporeal septation. J Urol. 1996 Feb;155(2):647–647. [PubMed] [Google Scholar]
  57. Hutch J. A., Fisher R. Continence after radical prostatectomy. Br J Urol. 1968 Feb;40(1):62–67. doi: 10.1111/j.1464-410x.1968.tb11813.x. [DOI] [PubMed] [Google Scholar]
  58. Johansson J. E. Expectant management of early stage prostatic cancer: Swedish experience. J Urol. 1994 Nov;152(5 Pt 2):1753–1756. doi: 10.1016/s0022-5347(17)32378-9. [DOI] [PubMed] [Google Scholar]
  59. Kahn D., Williams R. D., Haseman M. K., Reed N. L., Miller S. J., Gerstbrein J. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol. 1998 Jan;16(1):284–289. doi: 10.1200/JCO.1998.16.1.284. [DOI] [PubMed] [Google Scholar]
  60. Kahn D., Williams R. D., Manyak M. J., Haseman M. K., Seldin D. W., Libertino J. A., Maguire R. T. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. J Urol. 1998 Jun;159(6):2041–2047. doi: 10.1016/S0022-5347(01)63239-7. [DOI] [PubMed] [Google Scholar]
  61. Kattan M. W., Cowen M. E., Miles B. J. A decision analysis for treatment of clinically localized prostate cancer. J Gen Intern Med. 1997 May;12(5):299–305. doi: 10.1046/j.1525-1497.1997.012005299.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Kattan M. W., Eastham J. A., Stapleton A. M., Wheeler T. M., Scardino P. T. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998 May 20;90(10):766–771. doi: 10.1093/jnci/90.10.766. [DOI] [PubMed] [Google Scholar]
  63. Kattan M. W., Stapleton A. M., Wheeler T. M., Scardino P. T. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer. 1997 Feb 1;79(3):528–537. [PubMed] [Google Scholar]
  64. Kavoussi L. R., Myers J. A., Catalona W. J. Effect of temporary occlusion of hypogastric arteries on blood loss during radical retropubic prostatectomy. J Urol. 1991 Aug;146(2):362–365. doi: 10.1016/s0022-5347(17)37794-7. [DOI] [PubMed] [Google Scholar]
  65. Kim E. D., Scardino P. T., Hampel O., Mills N. L., Wheeler T. M., Nath R. K. Interposition of sural nerve restores function of cavernous nerves resected during radical prostatectomy. J Urol. 1999 Jan;161(1):188–192. [PubMed] [Google Scholar]
  66. Koch M. O., Smith J. A., Jr Influence of patient age and co-morbidity on outcome of a collaborative care pathway after radical prostatectomy and cystoprostatectomy. J Urol. 1996 May;155(5):1681–1684. [PubMed] [Google Scholar]
  67. Kuban D. A., el-Mahdi A. M., Schellhammer P. F. Effect of local tumor control on distant metastasis and survival in prostatic adenocarcinoma. Urology. 1987 Nov;30(5):420–426. doi: 10.1016/0090-4295(87)90372-4. [DOI] [PubMed] [Google Scholar]
  68. Kupelian P., Katcher J., Levin H., Zippe C., Suh J., Macklis R., Klein E. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. Cancer J Sci Am. 1997 Mar-Apr;3(2):78–87. [PubMed] [Google Scholar]
  69. Landis S. H., Murray T., Bolden S., Wingo P. A. Cancer statistics, 1999. CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1. doi: 10.3322/canjclin.49.1.8. [DOI] [PubMed] [Google Scholar]
  70. Lawton C. A., Won M., Pilepich M. V., Asbell S. O., Shipley W. U., Hanks G. E., Cox J. D., Perez C. A., Sause W. T., Doggett S. R. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys. 1991 Sep;21(4):935–939. doi: 10.1016/0360-3016(91)90732-j. [DOI] [PubMed] [Google Scholar]
  71. Leandri P., Rossignol G., Gautier J. R., Ramon J. Radical retropubic prostatectomy: morbidity and quality of life. Experience with 620 consecutive cases. J Urol. 1992 Mar;147(3 Pt 2):883–887. doi: 10.1016/s0022-5347(17)37412-8. [DOI] [PubMed] [Google Scholar]
  72. Lee F., Gray J. M., McLeary R. D., Meadows T. R., Kumasaka G. H., Borlaza G. S., Straub W. H., Lee F., Jr, Solomon M. H., McHugh T. A. Transrectal ultrasound in the diagnosis of prostate cancer: location, echogenicity, histopathology, and staging. Prostate. 1985;7(2):117–129. doi: 10.1002/pros.2990070202. [DOI] [PubMed] [Google Scholar]
  73. Leibel S. A., Hanks G. E., Kramer S. Patterns of care outcome studies: results of the national practice in adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1984 Mar;10(3):401–409. doi: 10.1016/0360-3016(84)90061-0. [DOI] [PubMed] [Google Scholar]
  74. Leibel S. A., Zelefsky M. J., Kutcher G. J., Burman C. M., Mohan R., Mageras G. S., Ling C. C., Fuks Z. The biological basis and clinical application of three-dimensional conformal external beam radiation therapy in carcinoma of the prostate. Semin Oncol. 1994 Oct;21(5):580–597. [PubMed] [Google Scholar]
  75. Lieber M. M. Practical clinical utility of DNA ploidy for managing patients with prostate carcinoma. Urology. 1995 Apr;45(4):558–562. doi: 10.1016/S0090-4295(99)80042-9. [DOI] [PubMed] [Google Scholar]
  76. Lilja H. Significance of different molecular forms of serum PSA. The free, noncomplexed form of PSA versus that complexed to alpha 1-antichymotrypsin. Urol Clin North Am. 1993 Nov;20(4):681–686. [PubMed] [Google Scholar]
  77. Litwin M. S., Flanders S. C., Pasta D. J., Stoddard M. L., Lubeck D. P., Henning J. M. Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology. 1999 Sep;54(3):503–508. doi: 10.1016/s0090-4295(99)00172-7. [DOI] [PubMed] [Google Scholar]
  78. Litwin M. S., Hays R. D., Fink A., Ganz P. A., Leake B., Leach G. E., Brook R. H. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA. 1995 Jan 11;273(2):129–135. doi: 10.1001/jama.273.2.129. [DOI] [PubMed] [Google Scholar]
  79. Massenkeil G., Oberhuber H., Hailemariam S., Sulser T., Diener P. A., Bannwart F., Schäfer R., Schwarte-Waldhoff I. P53 mutations and loss of heterozygosity on chromosomes 8p, 16q, 17p, and 18q are confined to advanced prostate cancer. Anticancer Res. 1994 Nov-Dec;14(6B):2785–2790. [PubMed] [Google Scholar]
  80. McNeal J. E. The zonal anatomy of the prostate. Prostate. 1981;2(1):35–49. doi: 10.1002/pros.2990020105. [DOI] [PubMed] [Google Scholar]
  81. McNeal J. E., Villers A. A., Redwine E. A., Freiha F. S., Stamey T. A. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer. 1990 Sep 15;66(6):1225–1233. doi: 10.1002/1097-0142(19900915)66:6<1225::aid-cncr2820660624>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  82. Mettlin C., Jones G. W., Murphy G. P. Trends in prostate cancer care in the United States, 1974-1990: observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer. CA Cancer J Clin. 1993 Mar-Apr;43(2):83–91. doi: 10.3322/canjclin.43.2.83. [DOI] [PubMed] [Google Scholar]
  83. Mettlin C., Murphy G. P., Lee F., Littrup P. J., Chesley A., Babaian R., Badalament R., Kane R. A., Mostofi F. K. Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project. Cancer. 1993 Sep 1;72(5):1701–1708. doi: 10.1002/1097-0142(19930901)72:5<1701::aid-cncr2820720534>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  84. Mohler J. L., Metts J. C., Zhang X. Z., Maygarden S. J. Nuclear morphometry in automatic biopsy and radical prostatectomy specimens of prostatic carcinoma. A comparison. Anal Quant Cytol Histol. 1994 Dec;16(6):415–420. [PubMed] [Google Scholar]
  85. Montie J. E., Wood D. P., Jr, Pontes J. E., Boyett J. M., Levin H. S. Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. Cancer. 1989 Jan 15;63(2):381–385. doi: 10.1002/1097-0142(19890115)63:2<381::aid-cncr2820630230>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  86. Mottaz A. E., Markwalder R., Fey M. F., Klima I., Merz V. W., Thalmann G. N., Ball R. K., Studer U. E. Abnormal p53 expression is rare in clinically localized human prostate cancer: comparison between immunohistochemical and molecular detection of p53 mutations. Prostate. 1997 Jun 1;31(4):209–215. doi: 10.1002/(sici)1097-0045(19970601)31:4<209::aid-pros1>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  87. Murphy G. P., Mettlin C., Menck H., Winchester D. P., Davidson A. M. National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer. J Urol. 1994 Nov;152(5 Pt 2):1817–1819. doi: 10.1016/s0022-5347(17)32392-3. [DOI] [PubMed] [Google Scholar]
  88. Natarajan N., Murphy G. P., Mettlin C. Prostate cancer in blacks: an update from the American College of Surgeons' patterns of care studies. J Surg Oncol. 1989 Apr;40(4):232–236. doi: 10.1002/jso.2930400406. [DOI] [PubMed] [Google Scholar]
  89. O'Donnell P. D., Finan B. F. Continence following nerve-sparing radical prostatectomy. J Urol. 1989 Nov;142(5):1227–1229. doi: 10.1016/s0022-5347(17)39038-9. [DOI] [PubMed] [Google Scholar]
  90. Ohori M., Goad J. R., Wheeler T. M., Eastham J. A., Thompson T. C., Scardino P. T. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol. 1994 Nov;152(5 Pt 2):1843–1849. doi: 10.1016/s0022-5347(17)32398-4. [DOI] [PubMed] [Google Scholar]
  91. Ohori M., Scardino P. T., Lapin S. L., Seale-Hawkins C., Link J., Wheeler T. M. The mechanisms and prognostic significance of seminal vesicle involvement by prostate cancer. Am J Surg Pathol. 1993 Dec;17(12):1252–1261. doi: 10.1097/00000478-199312000-00006. [DOI] [PubMed] [Google Scholar]
  92. Ohori M., Wheeler T. M., Dunn J. K., Stamey T. A., Scardino P. T. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol. 1994 Nov;152(5 Pt 2):1714–1720. doi: 10.1016/s0022-5347(17)32369-8. [DOI] [PubMed] [Google Scholar]
  93. Ohori M., Wheeler T. M., Kattan M. W., Goto Y., Scardino P. T. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol. 1995 Nov;154(5):1818–1824. [PubMed] [Google Scholar]
  94. Ohori M., Wheeler T. M., Scardino P. T. The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations. Cancer. 1994 Jul 1;74(1):104–114. doi: 10.1002/1097-0142(19940701)74:1<104::aid-cncr2820740119>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  95. Partin A. W., Carter H. B., Chan D. W., Epstein J. I., Oesterling J. E., Rock R. C., Weber J. P., Walsh P. C. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol. 1990 Apr;143(4):747–752. doi: 10.1016/s0022-5347(17)40079-6. [DOI] [PubMed] [Google Scholar]
  96. Partin A. W., Kattan M. W., Subong E. N., Walsh P. C., Wojno K. J., Oesterling J. E., Scardino P. T., Pearson J. D. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997 May 14;277(18):1445–1451. [PubMed] [Google Scholar]
  97. Partin A. W., Pound C. R., Clemens J. Q., Epstein J. I., Walsh P. C. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am. 1993 Nov;20(4):713–725. [PubMed] [Google Scholar]
  98. Peller P. A., Young D. C., Marmaduke D. P., Marsh W. L., Badalament R. A. Sextant prostate biopsies. A histopathologic correlation with radical prostatectomy specimens. Cancer. 1995 Jan 15;75(2):530–538. doi: 10.1002/1097-0142(19950115)75:2<530::aid-cncr2820750216>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  99. Perez C. A., Hanks G. E., Leibel S. A., Zietman A. L., Fuks Z., Lee W. R. Localized carcinoma of the prostate (stages T1B, T1C, T2, and T3). Review of management with external beam radiation therapy. Cancer. 1993 Dec 1;72(11):3156–3173. doi: 10.1002/1097-0142(19931201)72:11<3156::aid-cncr2820721106>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  100. Peters C. A., Walsh P. C. Blood transfusion and anesthetic practices in radical retropubic prostatectomy. J Urol. 1985 Jul;134(1):81–83. doi: 10.1016/s0022-5347(17)46991-6. [DOI] [PubMed] [Google Scholar]
  101. Pienta K. J., Demers R., Hoff M., Kau T. Y., Montie J. E., Severson R. K. Effect of age and race on the survival of men with prostate cancer in the Metropolitan Detroit tricounty area, 1973 to 1987. Urology. 1995 Jan;45(1):93–102. doi: 10.1016/s0090-4295(95)96996-9. [DOI] [PubMed] [Google Scholar]
  102. Pienta K. J., Esper P. S. Risk factors for prostate cancer. Ann Intern Med. 1993 May 15;118(10):793–803. doi: 10.7326/0003-4819-118-10-199305150-00007. [DOI] [PubMed] [Google Scholar]
  103. Pierce L. J., Whittington R., Hanno P. M., English W., Wein A. J., Goodman R. L. Pharmacologic erection with intracavernosal injection for men with sexual dysfunction following irradiation: a preliminary report. Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1311–1314. doi: 10.1016/0360-3016(91)90291-b. [DOI] [PubMed] [Google Scholar]
  104. Pilepich M. V., Krall J. M., al-Sarraf M., John M. J., Doggett R. L., Sause W. T., Lawton C. A., Abrams R. A., Rotman M., Rubin P. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology. 1995 Apr;45(4):616–623. doi: 10.1016/s0090-4295(99)80053-3. [DOI] [PubMed] [Google Scholar]
  105. Pound C. R., Partin A. W., Epstein J. I., Walsh P. C. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am. 1997 May;24(2):395–406. doi: 10.1016/s0094-0143(05)70386-4. [DOI] [PubMed] [Google Scholar]
  106. Reiner W. G., Walsh P. C. An anatomical approach to the surgical management of the dorsal vein and Santorini's plexus during radical retropubic surgery. J Urol. 1979 Feb;121(2):198–200. doi: 10.1016/s0022-5347(17)56718-x. [DOI] [PubMed] [Google Scholar]
  107. Rudy D. C., Woodside J. R., Crawford E. D. Urodynamic evaluation of incontinence in patients undergoing modified Campbell radical retropubic prostatectomy: a prospective study. J Urol. 1984 Oct;132(4):708–712. doi: 10.1016/s0022-5347(17)49836-3. [DOI] [PubMed] [Google Scholar]
  108. Sakr W. A., Grignon D. J., Crissman J. D., Heilbrun L. K., Cassin B. J., Pontes J. J., Haas G. P. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo. 1994 May-Jun;8(3):439–443. [PubMed] [Google Scholar]
  109. Sakr W. A., Macoska J. A., Benson P., Grignon D. J., Wolman S. R., Pontes J. E., Crissman J. D. Allelic loss in locally metastatic, multisampled prostate cancer. Cancer Res. 1994 Jun 15;54(12):3273–3277. [PubMed] [Google Scholar]
  110. Sandler H. M., McShan D. L., Lichter A. S. Potential improvement in the results of irradiation for prostate carcinoma using improved dose distribution. Int J Radiat Oncol Biol Phys. 1992;22(2):361–367. doi: 10.1016/0360-3016(92)90055-m. [DOI] [PubMed] [Google Scholar]
  111. Scardino P. T., Weaver R., Hudson M. A. Early detection of prostate cancer. Hum Pathol. 1992 Mar;23(3):211–222. doi: 10.1016/0046-8177(92)90102-9. [DOI] [PubMed] [Google Scholar]
  112. Schellhammer P., Cockett A., Boccon-Gibod L., Gospodarowicz M., Krongrad A., Thompson I. M., Scardino P., Soloway M., Adolfsson J. Assessment of endpoints for clinical trials for localized prostate cancer. Urology. 1997 Apr;49(4A):27–38. doi: 10.1016/s0090-4295(99)80321-5. [DOI] [PubMed] [Google Scholar]
  113. Shenfeld O. Z., Morgan C. W., Ratz P. H. Bethanechol activates a post-receptor negative feedback mechanism in rabbit urinary bladder smooth muscle. J Urol. 1998 Jan;159(1):252–257. doi: 10.1016/s0022-5347(01)64077-1. [DOI] [PubMed] [Google Scholar]
  114. Smit W. G., Helle P. A., van Putten W. L., Wijnmaalen A. J., Seldenrath J. J., van der Werf-Messing B. H. Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int J Radiat Oncol Biol Phys. 1990 Jan;18(1):23–29. doi: 10.1016/0360-3016(90)90262-i. [DOI] [PubMed] [Google Scholar]
  115. Smith J. R., Freije D., Carpten J. D., Grönberg H., Xu J., Isaacs S. D., Brownstein M. J., Bova G. S., Guo H., Bujnovszky P. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science. 1996 Nov 22;274(5291):1371–1374. doi: 10.1126/science.274.5291.1371. [DOI] [PubMed] [Google Scholar]
  116. Soloway M. S., Sharifi R., Wajsman Z., McLeod D., Wood D. P., Jr, Puras-Baez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol. 1995 Aug;154(2 Pt 1):424–428. [PubMed] [Google Scholar]
  117. Stanford J. L., Feng Z., Hamilton A. S., Gilliland F. D., Stephenson R. A., Eley J. W., Albertsen P. C., Harlan L. C., Potosky A. L. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA. 2000 Jan 19;283(3):354–360. doi: 10.1001/jama.283.3.354. [DOI] [PubMed] [Google Scholar]
  118. Steinberg G. D., Carter B. S., Beaty T. H., Childs B., Walsh P. C. Family history and the risk of prostate cancer. Prostate. 1990;17(4):337–347. doi: 10.1002/pros.2990170409. [DOI] [PubMed] [Google Scholar]
  119. Steiner M. S., Morton R. A., Walsh P. C. Impact of anatomical radical prostatectomy on urinary continence. J Urol. 1991 Mar;145(3):512–515. doi: 10.1016/s0022-5347(17)38382-9. [DOI] [PubMed] [Google Scholar]
  120. Svetec D., Thompson I. M. PSA screening--current controversy. Ann Oncol. 1998 Dec;9(12):1283–1288. doi: 10.1023/a:1008446208963. [DOI] [PubMed] [Google Scholar]
  121. Tefilli M. V., Gheiler E. L., Tiguert R., Banerjee M., Sakr W., Grignon D. J., Pontes J. E., Wood D. P., Jr Prognostic indicators in patients with seminal vesicle involvement following radical prostatectomy for clinically localized prostate cancer. J Urol. 1998 Sep;160(3 Pt 1):802–806. doi: 10.1016/S0022-5347(01)62791-5. [DOI] [PubMed] [Google Scholar]
  122. Ten Haken R. K., Perez-Tamayo C., Tesser R. J., McShan D. L., Fraass B. A., Lichter A. S. Boost treatment of the prostate using shaped, fixed fields. Int J Radiat Oncol Biol Phys. 1989 Jan;16(1):193–200. doi: 10.1016/0360-3016(89)90029-1. [DOI] [PubMed] [Google Scholar]
  123. Thompson I. M., Middleton R. G., Optenberg S. A., Austenfeld M. S., Smalley S. R., Cooner W. H., Correa R. J., Jr, Miller H. C., Jr, Oesterling J. E., Resnick M. I. Have complication rates decreased after treatment for localized prostate cancer? J Urol. 1999 Jul;162(1):107–112. doi: 10.1097/00005392-199907000-00026. [DOI] [PubMed] [Google Scholar]
  124. Trapasso J. G., deKernion J. B., Smith R. B., Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol. 1994 Nov;152(5 Pt 2):1821–1825. doi: 10.1016/s0022-5347(17)32394-7. [DOI] [PubMed] [Google Scholar]
  125. Ueda T., Ichikawa T., Tamaru J., Mikata A., Akakura K., Akimoto S., Imai T., Yoshie O., Shiraishi T., Yatani R. Expression of the KAI1 protein in benign prostatic hyperplasia and prostate cancer. Am J Pathol. 1996 Nov;149(5):1435–1440. [PMC free article] [PubMed] [Google Scholar]
  126. Umbas R., Isaacs W. B., Bringuier P. P., Schaafsma H. E., Karthaus H. F., Oosterhof G. O., Debruyne F. M., Schalken J. A. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res. 1994 Jul 15;54(14):3929–3933. [PubMed] [Google Scholar]
  127. Van Poppel H., Ameye F., Oyen R., Van De Voorde W., Baert L. Neo-adjuvant hormonotherapy does not facilitate radical prostatectomy. Acta Urol Belg. 1992;60(3):73–82. [PubMed] [Google Scholar]
  128. Ventura S. J., Peters K. D., Martin J. A., Maurer J. D. Births and deaths: United States, 1996. Mon Vital Stat Rep. 1997 Sep 11;46(1 Suppl 2):1–40. [PubMed] [Google Scholar]
  129. Walsh P. C. Anatomic radical prostatectomy: evolution of the surgical technique. J Urol. 1998 Dec;160(6 Pt 2):2418–2424. doi: 10.1097/00005392-199812020-00010. [DOI] [PubMed] [Google Scholar]
  130. Walsh P. C., Donker P. J. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol. 1982 Sep;128(3):492–497. doi: 10.1016/s0022-5347(17)53012-8. [DOI] [PubMed] [Google Scholar]
  131. Walsh P. C., Partin A. W., Epstein J. I. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol. 1994 Nov;152(5 Pt 2):1831–1836. doi: 10.1016/s0022-5347(17)32396-0. [DOI] [PubMed] [Google Scholar]
  132. Wheeler T. M., Dillioglugil O., Kattan M. W., Arakawa A., Soh S., Suyama K., Ohori M., Scardino P. T. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Hum Pathol. 1998 Aug;29(8):856–862. doi: 10.1016/s0046-8177(98)90457-9. [DOI] [PubMed] [Google Scholar]
  133. Wilt T. J., Brawer M. K. The Prostate Cancer Intervention Versus Observation Trial (PIVOT). Oncology (Williston Park) 1997 Aug;11(8):1133-9; discussion 1139-40, 1143. [PubMed] [Google Scholar]
  134. Wilt T. J., Brawer M. K. The Prostate Cancer Intervention Versus Observation Trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. J Urol. 1994 Nov;152(5 Pt 2):1910–1914. doi: 10.1016/s0022-5347(17)32413-8. [DOI] [PubMed] [Google Scholar]
  135. Xu J., Meyers D., Freije D., Isaacs S., Wiley K., Nusskern D., Ewing C., Wilkens E., Bujnovszky P., Bova G. S. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet. 1998 Oct;20(2):175–179. doi: 10.1038/2477. [DOI] [PubMed] [Google Scholar]
  136. Yang F. E., Chen G. T., Ray P., Vaida F., Chiru P., Hamilton R. J., Spelbring D., Abellera M., Vijayakumar S. The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer. Int J Radiat Oncol Biol Phys. 1995 Dec 1;33(5):1009–1017. doi: 10.1016/0360-3016(95)02064-0. [DOI] [PubMed] [Google Scholar]
  137. Zagars G. K., von Eschenbach A. C., Ayala A. G., Schultheiss T. E., Sherman N. E. The influence of local control on metastatic dissemination of prostate cancer treated by external beam megavoltage radiation therapy. Cancer. 1991 Dec 1;68(11):2370–2377. doi: 10.1002/1097-0142(19911201)68:11<2370::aid-cncr2820681107>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  138. Zelefsky M. J., Eid J. F. Elucidating the etiology of erectile dysfunction after definitive therapy for prostatic cancer. Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):129–133. doi: 10.1016/s0360-3016(97)00554-3. [DOI] [PubMed] [Google Scholar]
  139. Zelefsky M. J., Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. Urology. 1997 Mar;49(3A):38–45. doi: 10.1016/s0090-4295(97)00168-4. [DOI] [PubMed] [Google Scholar]
  140. Zelefsky M. J., Leibel S. A., Burman C. M., Kutcher G. J., Harrison A., Happersett L., Fuks Z. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):755–761. doi: 10.1016/0360-3016(94)90563-0. [DOI] [PubMed] [Google Scholar]
  141. Zelefsky M. J., Leibel S. A., Gaudin P. B., Kutcher G. J., Fleshner N. E., Venkatramen E. S., Reuter V. E., Fair W. R., Ling C. C., Fuks Z. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):491–500. doi: 10.1016/s0360-3016(98)00091-1. [DOI] [PubMed] [Google Scholar]
  142. Zelefsky M. J., Leibel S. A., Kutcher G. J., Kelson S., Ling C. C., Fuks Z. The feasibility of dose escalation with three-dimensional conformal radiotherapy in patients with prostatic carcinoma. Cancer J Sci Am. 1995 Jul-Aug;1(2):142–150. [PubMed] [Google Scholar]
  143. Zelefsky M. J., McKee A. B., Lee H., Leibel S. A. Efficacy of oral sildenafil in patients with erectile dysfunction after radiotherapy for carcinoma of the prostate. Urology. 1999 Apr;53(4):775–778. doi: 10.1016/s0090-4295(98)00594-9. [DOI] [PubMed] [Google Scholar]
  144. Zincke H., Oesterling J. E., Blute M. L., Bergstralh E. J., Myers R. P., Barrett D. M. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol. 1994 Nov;152(5 Pt 2):1850–1857. doi: 10.1016/s0022-5347(17)32399-6. [DOI] [PubMed] [Google Scholar]
  145. Zuckerman S. The Endocrine Control of the Prostate: (Section of Urology). Proc R Soc Med. 1936 Oct;29(12):1557–1568. doi: 10.1177/003591573602901207. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Transactions of the American Clinical and Climatological Association are provided here courtesy of American Clinical and Climatological Association

RESOURCES